Alnylam Pharmaceuticals

675 W. Kendall St.
Cambridge,  MA  02142

United States
  • Booth: 1201

About Alnylam Pharmaceuticals Alnylam is leading the translation of RNA interference (RNAi) into a new class of medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics are a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is headquartered in Cambridge, MA. For more information visit